Liquidia Technologies LQDA 深 沪
等待开盘 08-19 09:30:00 美东时间
74.33
-3.370
-4.34%
华盛通- 最 高76.77
- 今 开76.20
- 成交量 144.75万股
- 最 低 72.8302
- 昨 收 77.70
- 总市值 66.53亿
- 52周最高 93.61
- 市盈率 静 --
- 换手率 1.62%
- 52周最低 21.145
- 委 比 71.67%
- 总股本 8950.89万
- 历史最高 93.61
- 量 比 0.51
- 振 幅 5.07%
- 历史最低 2.25
- 每 手 1
- 风险率 19.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
Liquidia (LQDA) 2026年第二季度业绩电话会议：YUTREPIA销售额增长31%
Liquidia 的 2026 年第二季度业绩电话会议涵盖了 YUTREPIA 达 1.704 亿美元的销售额、31% 的季度增长、利润上升、管线支出及其 2027 年目标。
08-14 08:27
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
Liquidia shares are trading lower despite reporting better-than-expected Q2 financial results. The stock may be experiencing some profit taking after rising approximately 200% since the end of March.
Liquidia shares are trading lower despite reporting better-than-expected Q2 financial results. The stock may be experiencing some profit taking after rising approximately 200% since the end of March.
08-12 21:29
Liquidia Technologies reports strong Q2 growth and profitability
Liquidia Technologies ( ($LQDA) ) just unveiled an announcement. On August 12, ...
08-12 19:18
财报速睇 | Liquidia Technologies 2026财年Q2营收1.72亿美元，同比增长1842.9%；归母净利润0.75亿美元，扭亏为盈
华盛资讯8月12日讯，Liquidia Technologies公布2026财年Q2业绩，公司Q2营收1.72亿美元，同比增长1842.9%，归母净利润0.75亿美元，扭亏为盈。
08-12 19:07
财报速睇 | Liquidia Technologies 2026财年Q2营收1.72亿美元，同比增长1842.8%；归母净利润0.75亿美元，扭亏为盈
华盛资讯8月12日讯，Liquidia Technologies公布2026财年Q2业绩，公司Q2营收1.72亿美元，同比增长1842.8%，归母净利润0.75亿美元，扭亏为盈。
08-12 19:02
Liquidia Q2 EPS $0.74 Beats $0.41 Estimate, Sales $171.679M Beat $116.675M Estimate
Liquidia (NASDAQ:LQDA) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.41 by 80.49 percent. This is a 251.02 percent increase over losses of $(0.49) per share from the same period last year. The company reported quarterly sales of $171.679 million which...
08-12 18:39
Liquidia Corporation Reports Second Quarter 2026 Financial Results
Liquidia Corporation reported strong financial results for Q2 2026, with YUTREPIA sales reaching $170.4 million, up 31% from Q1 2026. The company achieved net income of $74.7 million and adjusted EBITDA of $96.3 million, marking the fourth consecutive quarter of increasing profitability. Since its launch in June 2025, YUTREPIA has been prescribed to approximately 5,900 unique patients, with over 5,000 treated. Liquidia is advancing 10 clinical st...
08-12 10:30
SA Asks: What's the outlook for Big Pharma M&A?
Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY) was in merger talks with AstraZeneca (AZN), a development that was later denied by...
08-09 03:28
